

# Hongjuan Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11398532/publications.pdf>

Version: 2024-02-01

43  
papers

2,683  
citations

249298

26  
h-index

286692

43  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4717  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging. <i>International Journal of Cancer</i> , 2020, 147, 256-265.	2.3	38
2	<i>Sprr2f</i> protects against renal injury by decreasing the level of reactive oxygen species in female mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F876-F884.	1.3	6
3	The m <sup>6</sup> A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21441-21449.	3.3	56
4	Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry. <i>Scientific Reports</i> , 2019, 9, 11007.	1.6	12
5	S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma. <i>Cancer Research</i> , 2019, 79, 5758-5768.	0.4	39
6	miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 119-132.	0.2	9
7	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33
8	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 109-119.	1.9	45
9	Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. <i>Cancer Biology and Therapy</i> , 2017, 18, 863-871.	1.5	28
10	Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 325-337.	1.7	16
11	A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data. <i>PLoS ONE</i> , 2016, 11, e0146505.	1.1	42
12	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. <i>Radiology</i> , 2015, 277, 114-123.	3.6	61
13	Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. <i>Oncotarget</i> , 2015, 6, 43172-43181.	0.8	43
14	Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 573-584.	1.7	17
15	Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. <i>International Journal of Cancer</i> , 2014, 134, 2322-2329.	2.3	40
16	Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. <i>Cancer Letters</i> , 2014, 351, 272-280.	3.2	16
17	A Tissue Graft Model of DNA Damage Response in the Normal and Malignant Human Prostate. <i>Journal of Urology</i> , 2014, 191, 842-849.	0.2	5
18	Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic potential. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 43.e23-43.e30.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. <i>Journal of Translational Medicine</i> , 2013, 11, 199.	1.8	18
20	Induced Pluripotency of Human Prostatic Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e64503.	1.1	15
21	Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer. <i>Clinical Cancer Research</i> , 2012, 18, 3366-3376.	3.2	20
22	Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression. <i>Journal of Urology</i> , 2012, 188, 2158-2164.	0.2	26
23	Targeting monoamine oxidase A in advanced prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1761-1771.	1.2	66
24	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. <i>Genes and Cancer</i> , 2010, 1, 152-163.	0.6	283
25	Tissue Slice Grafts. <i>American Journal of Pathology</i> , 2010, 177, 229-239.	1.9	56
26	Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas. <i>PLoS ONE</i> , 2009, 4, e6039.	1.1	15
27	Tumor-promoting phenotype of CD90 <sup>hi</sup> prostate cancer-associated fibroblasts. <i>Prostate</i> , 2009, 69, 991-1000.	1.2	71
28	CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. <i>BMC Clinical Pathology</i> , 2009, 9, 9.	1.8	30
29	Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. <i>BMC Medical Genomics</i> , 2009, 2, 55.	0.7	29
30	Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. <i>Differentiation</i> , 2008, 76, 820-830.	1.0	29
31	The Significance of Monoamine Oxidase-A Expression in High Grade Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 2206-2211.	0.2	53
32	A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. <i>Nucleic Acids Research</i> , 2007, 35, 2767-2776.	6.5	45
33	Selenomethionine Induced Transcriptional Programs in Human Prostate Cancer Cells. <i>Journal of Urology</i> , 2007, 177, 743-750.	0.2	22
34	Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. <i>Journal of Cellular Physiology</i> , 2007, 210, 111-121.	2.0	49
35	Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. <i>Prostate</i> , 2005, 63, 187-197.	1.2	62
36	Molecular targets of doxazosin in human prostatic stromal cells. <i>Prostate</i> , 2005, 62, 400-410.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma. PLoS Medicine, 2005, 3, e13.	3.9	182
38	Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics and Proteomics, 2005, 2, 97-114.	1.0	23
39	Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast. Molecular Biology of the Cell, 2004, 15, 2523-2536.	0.9	540
40	Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells. Molecular Biology of the Cell, 2004, 15, 506-519.	0.9	100
41	Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics, 2002, 3, 31.	1.2	124
42	A Conserved Mechanism of Synaptogyrin Localization. Molecular Biology of the Cell, 2001, 12, 2275-2289.	0.9	23
43	Synaptic Transmission Deficits in <i>Caenorhabditis elegans</i> Synaptobrevin Mutants. Journal of Neuroscience, 1998, 18, 70-80.	1.7	253